Why the study?
Does Klkb1 deficiency or Mas receptor modulation alter thrombosis times in mice?
Does Klkb1 deficiency or Mas receptor modulation alter thrombosis times in mice?
Klkb1 deficiency protects against thrombosis through a novel pathway involving increased Mas receptor, prostacyclin, Sirt1, and KLF4, leading to reduced vascular tissue factor.
Answers are grounded in this paper and cite their sources.
Should not alter clinical antithrombotic practice; hypothesis-generating for Mas-Sirt1 pathway in human thrombosis research.
The precise mechanism for reduced thrombosis in prekallikrein null mice (Klkb1(-/-)) is unknown. Klkb1(-/-) mice have delayed carotid artery occlusion times on the rose bengal and ferric chloride thrombosis models. Klkb1(-/-) plasmas have long-activated partial thromboplastin times and defective contact activation-induced thrombin generation that partially corrects upon prolonged incubation. However, in contact activation-induced pulmonary thromboembolism by collagen/epinephrine or long-chain polyphosphate, Klkb1(-/-) mice, unlike F12(-/-) mice, do not have survival advantage. Klkb1(-/-) mice have reduced plasma BK levels and renal B2R mRNA. They also have increased expression of the renal receptor Mas and plasma prostacyclin. Increased prostacyclin is associated with elevated aortic vasculoprotective transcription factors Sirt1 and KLF4. Treatment of Klkb1(-/-) mice with the Mas antagonist A-779, COX-2 inhibitor nimesulide, or Sirt1 inhibitor splitomicin lowers plasma prostacyclin and normalizes arterial thrombosis times. Treatment of normal mice with the Mas agonist AVE0991 reduces thrombosis. Klkb1(-/-) mice have reduced aortic tissue factor (TF) mRNA, antigen, and activity. In sum, Klkb1(-/-) mice have a novel mechanism for thrombosis protection in addition to reduced contact activation. This pathway arises when bradykinin delivery to vasculature is compromised and mediated by increased receptor Mas, prostacyclin, Sirt1, and KLF4, leading to reduced vascular TF.
No takes yet. Share an insight, caveat, or question.
Stavrou et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: